Literature DB >> 12540787

Endoscopic screening for esophageal varices in cirrhosis: Is it ever cost effective?

Brennan M r Spiegel1, Laura Targownik, Gareth S Dulai, Hetal A Karsan, Ian M Gralnek.   

Abstract

Current guidelines for the management of patients with compensated cirrhosis recommend universal screening endoscopy followed by prophylactic beta-blocker therapy to prevent initial hemorrhage in those found to have esophageal varices. However, the cost-effectiveness of this recommendation has not been established. Our objective was to determine whether screening endoscopy is cost-effective compared with empiric medical management in patients with compensated cirrhosis. Decision analysis with Markov modeling was used to calculate the cost-effectiveness of 6 competing strategies: (1) universal screening endoscopy (EGD) followed by beta-blocker (BB) therapy (EGD-->BB) if varices are present, (2) EGD followed by endoscopic band ligation (EBL) (EGD-->EBL) if varices are present, (3) selective screening endoscopy (sEGD) in high risk patients followed by BB therapy if varices are present (sEGD-->BB), (4) selective screening endoscopy followed by EBL (sEGD-->EBL) if varices are present, (5) empiric beta-blocker therapy in all patients, and (6) no prophylactic therapy ("Do Nothing"). Cost estimates were from a third-party payer perspective. The main outcome measure was the cost per initial variceal hemorrhage prevented. The "Do Nothing" strategy was the least expensive yet least effective approach. Compared with the "Do Nothing" strategy, the empiric beta-blocker strategy cost an incremental $12,408 per additional variceal bleed prevented. Compared with the empiric beta-blocker strategy, in turn, both the EGD-->BB and the EGD-->EBL strategies cost over $175,000 more per additional bleed prevented. The sEGD-->BB and sEGD-->EBL strategies were more expensive and less effective than the empiric beta-blocker strategy. In conclusion, empiric beta-blocker therapy for the primary prophylaxis of variceal hemorrhage is a cost-effective measure, as the use of screening endoscopy to guide therapy adds significant cost with only marginal increase in effectiveness.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12540787     DOI: 10.1053/jhep.2003.50050

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  21 in total

1.  High-risk esophageal varices in patients treated with locoregional therapies for hepatocellular carcinoma: evaluation with regular follow-up liver CT.

Authors:  Hyojin Kim; Dongil Choi; Geum-Youn Gwak; Joon Hyeok Lee; Soon Jin Lee; Seong Hyun Kim; Ji Young Lee; Yulri Park; Ilsoo Chang; Hyo K Lim
Journal:  Dig Dis Sci       Date:  2008-12-03       Impact factor: 3.199

2.  External validation of the platelet count/spleen diameter ratio for the diagnosis of esophageal varices in hepatitis C virus-related cirrhosis.

Authors:  Adnan Agha; Eram Anwar; Kaukab Bashir; Vincenzo Savarino; Edoardo G Giannini
Journal:  Dig Dis Sci       Date:  2008-07-02       Impact factor: 3.199

Review 3.  Platelet count, spleen length, and platelet count-to-spleen length ratio for the diagnosis of oesophageal varices in people with chronic liver disease or portal vein thrombosis.

Authors:  Agostino Colli; Juan Cristóbal Gana; Jason Yap; Thomasin Adams-Webber; Natalie Rashkovan; Simon C Ling; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2017-04-26

4.  Cost-effectiveness analysis of beta-blockers vs endoscopic surveillance in patients with cirrhosis and small varices.

Authors:  Lorenza Di Pascoli; Alessandra Buja; Massimo Bolognesi; Sara Montagnese; Angelo Gatta; Dario Gregori; Carlo Merkel
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

5.  Role of non-invasive markers in prediction of esophageal varices and variceal bleeding in patients of alcoholic liver cirrhosis from central India.

Authors:  Harit Goverdhan Kothari; Sudhir Jagdishoprasad Gupta; Nitin Rangrao Gaikwad; Tushar Hiralal Sankalecha; Amol Rajendra Samarth
Journal:  Turk J Gastroenterol       Date:  2019-12       Impact factor: 1.852

6.  Diagnostic non-invasive model of large risky esophageal varices in cirrhotic hepatitis C virus patients.

Authors:  Hatem Elalfy; Walid Elsherbiny; Ashraf Abdel Rahman; Dina Elhammady; Shaker Wagih Shaltout; Ayman Z Elsamanoudy; Bassem El Deek
Journal:  World J Hepatol       Date:  2016-08-28

Review 7.  Capsule endoscopy for the diagnosis of oesophageal varices in people with chronic liver disease or portal vein thrombosis.

Authors:  Agostino Colli; Juan Cristóbal Gana; Dan Turner; Jason Yap; Thomasin Adams-Webber; Simon C Ling; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2014-10-01

8.  Hospitalized Patients with Cirrhosis Should Be Screened for Clostridium difficile Colitis.

Authors:  Sammy Saab; Theodore Alper; Ernesto Sernas; Paridhima Pruthi; Mikhail A Alper; Vinay Sundaram
Journal:  Dig Dis Sci       Date:  2015-05-19       Impact factor: 3.199

Review 9.  Non-invasive tests for the detection of oesophageal varices in compensated cirrhosis: systematic review and meta-analysis.

Authors:  Sarmed S Sami; David Harman; Krish Ragunath; Dankmar Böhning; Julie Parkes; Indra Neil Guha
Journal:  United European Gastroenterol J       Date:  2018-03-22       Impact factor: 4.623

10.  Description and prediction of the development of metabolic syndrome: a longitudinal analysis using a markov model approach.

Authors:  Lee-Ching Hwang; Chyi-Huey Bai; San-Lin You; Chien-An Sun; Chien-Jen Chen
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.